Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abrocitinib

FDA-approved product (tablet, oral), marketed as Cibinqo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Abrocitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Eczematoid dermatitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abrocitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abrocitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

    NCT05602207 · start 2022-11-25

    Registered record
    Registry ID
    NCT05602207
    Conditions
    Atopic Dermatitis
    Interventions
    Abrocitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-11-25
    Completion
    2025-01-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionAbrocitinib
    PhasePhase 4
    Registry statusCompleted

  • A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

    NCT05375929 · start 2022-07-16

    Registered record
    Registry ID
    NCT05375929
    Conditions
    Atopic Dermatitis
    Interventions
    Abrocitinib 100 mg; Abrocitinib 200 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-07-16
    Completion
    2024-03-14
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionAbrocitinib 100 mg; Abrocitinib 200 mg
    PhasePhase 3
    Registry statusCompleted

  • JAK Inhibition in Food Allergy

    NCT05069831 · start 2022-05-16

    Registered record
    Registry ID
    NCT05069831
    Conditions
    Food Allergy
    Interventions
    Abrocitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-05-16
    Completion
    2025-06-13
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFood Allergy
    InterventionAbrocitinib
    PhasePhase 1
    Registry statusCompleted

  • A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

    NCT05250115 · start 2022-05-10

    Registered record
    Registry ID
    NCT05250115
    Conditions
    Dermatitis, Atopic
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2022-05-10
    Completion
    2024-07-25
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

    NCT05387980 · start 2022-04-19

    Registered record
    Registry ID
    NCT05387980
    Conditions
    Atopic Dermatitis
    Interventions
    CIBINQO
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2022-04-19
    Completion
    2028-11-01
    Enrolment
    1,128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionCIBINQO
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

    NCT05067439 · start 2021-10-21

    Registered record
    Registry ID
    NCT05067439
    Conditions
    Healthy Participants
    Interventions
    Abrocitinib; Omeprazole; Caffeine; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-10-21
    Completion
    2022-02-26
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAbrocitinib; Omeprazole; Caffeine; Efavirenz
    PhasePhase 1
    Registry statusCompleted

  • Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin

    NCT05038982 · start 2021-09-09

    Registered record
    Registry ID
    NCT05038982
    Conditions
    Prurigo Nodularis; Pruritus; Chronic Pruritus; Chronic Prurigo; Skin Diseases
    Interventions
    Abrocitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-09
    Completion
    2022-07-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrurigo Nodularis; Pruritus; Chronic Pruritus; Chronic Prurigo +1 more
    InterventionAbrocitinib
    PhasePhase 2
    Registry statusCompleted

  • A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

    NCT04903093 · start 2021-06-04

    Registered record
    Registry ID
    NCT04903093
    Conditions
    Healthy Volunteers
    Interventions
    Abrocitinib tablet; Abrocitinib Suspension F1; Abrocitinib Suspension F2; Abrocitinib Suspension F3; Abrocitinib Suspension F4; Abrocitinib Suspension F5; Abrocitinib Suspension F6; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-06-04
    Completion
    2021-10-26
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAbrocitinib tablet; Abrocitinib Suspension F1; Abrocitinib Suspension F2; Abrocitinib Suspension F3 +4 more
    PhasePhase 1
    Registry statusCompleted

  • Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

    NCT03915496 · start 2020-06-18

    Registered record
    Registry ID
    NCT03915496
    Conditions
    Atopic Dermatitis
    Interventions
    PF-04965842 200 mg; PF-04965842 100 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-06-18
    Completion
    2021-11-16
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPF-04965842 200 mg; PF-04965842 100 mg; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

    NCT04345367 · start 2020-06-11

    Registered record
    Registry ID
    NCT04345367
    Conditions
    Atopic Dermatitis
    Interventions
    Abrocitinib 200 mg; Dupilumab 300 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-06-11
    Completion
    2021-07-13
    Enrolment
    727

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionAbrocitinib 200 mg; Dupilumab 300 mg
    PhasePhase 3
    Registry statusCompleted

  • Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants

    NCT04099563 · start 2019-10-14

    Registered record
    Registry ID
    NCT04099563
    Conditions
    HEALTHY
    Interventions
    PF-04965842
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-10-14
    Completion
    2019-12-09
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHEALTHY
    InterventionPF-04965842
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants

    NCT03937258 · start 2019-05-21

    Registered record
    Registry ID
    NCT03937258
    Conditions
    Healthy
    Interventions
    PF-04965842; Probenecid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-05-21
    Completion
    2019-07-26
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-04965842; Probenecid
    PhasePhase 1
    Registry statusCompleted

  • JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

    NCT03796676 · start 2019-02-18

    Registered record
    Registry ID
    NCT03796676
    Conditions
    Atopic Dermatitis
    Interventions
    Placebo; PF-04965842; PF04965842
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-02-18
    Completion
    2020-04-08
    Enrolment
    287

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPlacebo; PF-04965842; PF04965842
    PhasePhase 3
    Registry statusCompleted

  • Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants

    NCT03806101 · start 2019-01-23

    Registered record
    Registry ID
    NCT03806101
    Conditions
    Healthy
    Interventions
    PF-04965842; Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-01-23
    Completion
    2019-04-11
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-04965842; Rosuvastatin
    PhasePhase 1
    Registry statusCompleted

  • Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants

    NCT03796182 · start 2019-01-10

    Registered record
    Registry ID
    NCT03796182
    Conditions
    Healthy
    Interventions
    Metformin; PF-04965842
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-01-10
    Completion
    2019-03-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMetformin; PF-04965842
    PhasePhase 1
    Registry statusCompleted